PRMA Consulting - Fishawack Health
Cytiva

C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Novel Repotrectinib Therapeutic Option Discovered for Advanced Solid Tumors

Turning Point Therapeutics, Inc discovered novel repotrectinib, a leading drug candidate for the treatment of patients with advanced solid tumors having an NTRK gene fusion.

Repotrectinib is a therapeutic option for patients who have shown progress with 1 or 2 prior TRK TKIs after treatment, with or without prior chemotherapy and for patients who remain with no other options.

Repotrectinib consists of a small macrocyclic TKI of ROS1, TRK, and ALK. It is bind with the active kinase conformation and avoids steric interference from several clinically-resistant mutations.

Repotrectinib has also been granted an Orphan Drug designation in 2017. U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to lead drug candidate, repotrectinib for the treatment of TKI-pretreated advanced solid tumors.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA Catalent - Clinical Supply Solutions MasterControl - Choose the Modern Manufacturing Software That’s Right for You Medical Fair Asia 2022 Medical Manufacturing Asia 2022